{"id":2611,"date":"2018-04-12T17:12:16","date_gmt":"2018-04-12T11:42:16","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2611"},"modified":"2021-07-24T12:56:58","modified_gmt":"2021-07-24T07:26:58","slug":"business-cocktail-latest-pharma-news-4","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news-4","title":{"rendered":"Cellectis successfully bags USD 164 million for Gene-editing and CAR-T programs"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>Cellectis successfully bags USD 164 million for Gene-editing and CAR-T programs<\/strong><\/p>\n<p style=\"text-align: justify;\">After a rough journey in 2017, the road seems clear for French CAR-T specialist Cellectis, which has recently closed a USD 164 million U.S. public offering. Out of total funding amount around USD 100 million will be used to build commercial infrastructure including a manufacturing plant for its CAR-T candidates. It uses donated cells rather than cells harvested from individual patients.<\/p>\n<p style=\"text-align: justify;\"><strong>Alexion to takeover Wilson Therapeutics for USD 855 million<\/strong><\/p>\n<p style=\"text-align: justify;\">Alexion has\u00a0signed a deal worth\u00a0USD 855 million to acquire Wilson Therapeutics. The takeover will provide Alexion control over WTX101, a phase 3 treatment for the rare genetic disorder Wilson disease. Rare disease specialist Alexion spent last year cutting down its pipeline programs, partnerships and staff in preparation for an expected decline in sales of Soliris.<\/p>\n<p style=\"text-align: justify;\"><strong>Ayala snatched USD 17 million in financing to drive BMS drug into phase 2<\/strong><\/p>\n<p style=\"text-align: justify;\">Founded last year as a development medium for two of Bristol-Myers Squibb\u2019s cancer candidates, Israeli biotech Ayala Pharmaceuticals has raised USD 17 million in series A financing. Ayala has licensed\u00a0rights to BMS\u2019s gamma secretase inhibitor BMS-906024 in December last year. The deal also included a follow-up drug i.e. BMS-986115, and involved an undisclosed upfront fee to BMS plus milestones and royalties. Both the drugs have successfully passed though phase 1 testing.<\/p>\n<p style=\"text-align: justify;\"><strong>Investment firm Frazier Healthcare Partners closes USD 780 million growth buyout fund<\/strong><\/p>\n<p style=\"text-align: justify;\">Frazier Healthcare Partners has closed another fund worth USD 780 million that will be used support established companies in accelerating their growth. The fund was meant for healthcare companies in the lower middle market, which means companies in the\u00a0healthcare and pharmaceutical services and medical products sectors\u00a0with operating earnings of around USD 5 million to USD 50 million.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cellectis successfully bags USD 164 million for Gene-editing and CAR-T programs After a rough journey in 2017, the road seems clear for French CAR-T specialist Cellectis, which has recently closed a USD 164 million U.S. public offering. Out of total funding amount around USD 100 million will be used to build commercial infrastructure including a [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[885,1568,1569,1468,1118,810,1007,1342,204,1570,657,381,1230,706,1567,1565,1566],"industry":[17225],"therapeutic_areas":[17235,17228,17234],"class_list":["post-2611","post","type-post","status-publish","format-standard","hentry","category-notizia","tag-alexion","tag-ayala","tag-bms-986115","tag-bristol-myers-squibbs","tag-business-research","tag-car-t","tag-cellectis","tag-consulting","tag-delveinsight","tag-frazier-healthcare-partners","tag-gene-editing","tag-market-research","tag-pharma-consultancy","tag-pharmaceutical-industry","tag-soliris","tag-wilson-therapeutics","tag-wtx101","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-oncology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Cellectis rasies $164M; Wilson&#039;s takeover; Ayala-BMS pact; Frazier&#039;s deal<\/title>\n<meta name=\"description\" content=\"After a rough journey in 2017, the road seems clear for French CAR-T specialist Cellectis, which has recently closed a USD 164 million U.S. public offering.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news-4\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cellectis rasies $164M; Wilson&#039;s takeover; Ayala-BMS pact; Frazier&#039;s deal\" \/>\n<meta property=\"og:description\" content=\"After a rough journey in 2017, the road seems clear for French CAR-T specialist Cellectis, which has recently closed a USD 164 million U.S. public offering.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news-4\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-04-12T11:42:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:26:58+00:00\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Cellectis rasies $164M; Wilson's takeover; Ayala-BMS pact; Frazier's deal","description":"After a rough journey in 2017, the road seems clear for French CAR-T specialist Cellectis, which has recently closed a USD 164 million U.S. public offering.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news-4","og_locale":"en_US","og_type":"article","og_title":"Cellectis rasies $164M; Wilson's takeover; Ayala-BMS pact; Frazier's deal","og_description":"After a rough journey in 2017, the road seems clear for French CAR-T specialist Cellectis, which has recently closed a USD 164 million U.S. public offering.","og_url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news-4","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-04-12T11:42:16+00:00","article_modified_time":"2021-07-24T07:26:58+00:00","author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news-4","url":"https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news-4","name":"Cellectis rasies $164M; Wilson's takeover; Ayala-BMS pact; Frazier's deal","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"datePublished":"2018-04-12T11:42:16+00:00","dateModified":"2021-07-24T07:26:58+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"After a rough journey in 2017, the road seems clear for French CAR-T specialist Cellectis, which has recently closed a USD 164 million U.S. public offering.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/business-cocktail-latest-pharma-news-4"]}]},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":null,"coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Alexion<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ayala<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">BMS-986115<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Bristol-Myers Squibb\u2019s<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">business research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">CAR-T<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Cellectis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">consulting<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Frazier Healthcare Partners<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gene editing<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Market Research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">pharma consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Pharmaceutical Industry<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Soliris<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Wilson Therapeutics<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">WTX101<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Alexion<\/span>","<span class=\"advgb-post-tax-term\">Ayala<\/span>","<span class=\"advgb-post-tax-term\">BMS-986115<\/span>","<span class=\"advgb-post-tax-term\">Bristol-Myers Squibb\u2019s<\/span>","<span class=\"advgb-post-tax-term\">business research<\/span>","<span class=\"advgb-post-tax-term\">CAR-T<\/span>","<span class=\"advgb-post-tax-term\">Cellectis<\/span>","<span class=\"advgb-post-tax-term\">consulting<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">Frazier Healthcare Partners<\/span>","<span class=\"advgb-post-tax-term\">Gene editing<\/span>","<span class=\"advgb-post-tax-term\">Market Research<\/span>","<span class=\"advgb-post-tax-term\">pharma consultancy<\/span>","<span class=\"advgb-post-tax-term\">Pharmaceutical Industry<\/span>","<span class=\"advgb-post-tax-term\">Soliris<\/span>","<span class=\"advgb-post-tax-term\">Wilson Therapeutics<\/span>","<span class=\"advgb-post-tax-term\">WTX101<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Apr 12, 2018","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Apr 12, 2018 5:12 pm","modified":"Updated on Jul 24, 2021 12:56 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2611","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2611"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2611\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2611"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2611"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2611"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2611"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2611"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}